Survival impact of previous statin therapy in patients hospitalized with COVID-19
Med Clin (Barc). 2023 Jan 5;160(1):1-9.
doi: 10.1016/j.medcli.2022.03.015.
Epub 2022 May 8.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Cardiología, Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, España; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, España; Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, España. Electronic address: eduardo.barge.caballero@sergas.es.
- 2 Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, España; Servicio de Neumología, CHUAC, A Coruña, España.
- 3 Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, España; Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, España.
- 4 Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, España; Servicio de Microbiología, CHUAC, A Coruña, España.
- 5 Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, España; Servicio de Inmunología Clínica, CHUAC, A Coruña, España.
- 6 Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, España.
- 7 Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, España; Departamento de Ciencias de la Salud, Universidad de A Coruña, A Coruña, España.
- 8 Servicio de Cardiología, Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, España; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, España; Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, España.
Abstract
Introduction:
Statin therapy might have a beneficial prognostic effect in patients with COVID-19, given its immunomodulative, anti-inflammatory and anti-atherosclerotic properties. Our purpose was to test this hypothesis by using the COVID-19 registry of a Spanish university hospital.
Methods:
We conducted a single-center, observational and retrospective study in which hospitalized patients with COVID-19 diagnosed by PCR between March 2020 and October 2020 were included. By means of logistic regression, we designed a propensity score to estimate the likelihood that a patient would receive statin treatment prior to admission. We compared the survival of COVID-19 patients with and without statin treatment by means of Cox regression with inverse probability of treatment weighting (IPTW). The median follow-up was 406 days.
Results:
We studied 1122 hospitalized patients with COVID-19, whose median age was 71years and of which 488 (43.5%) were women. 451 (40.2%) patients received statins before admission. In the IPTW survival analysis, prior statin treatment was associated with a significant reduction in mortality (HR: 0.76; 95%CI: 0.59-0.97). The greatest benefit of previous statin therapy was seen in subgroups of patients with coronary artery disease (HR: 0.32; 95%CI: 0.18-0.56) and extracardiac arterial disease (HR: 0.45; 95%CI: 0.28-0.73).
Conclusions:
Our study showed a significant association between previous treatment with statins and lower mortality in hospitalized patients with COVID-19. The observed prognostic benefit was greater in patients with previous coronary or extracardiac atherosclerotic disease.
Keywords:
COVID-19; Estatinas; SARS-CoV-2; Statins; Supervivencia; Survival.
Copyright © 2022 Elsevier España, S.L.U. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Atherosclerosis*
-
COVID-19*
-
Coronary Artery Disease*
-
Female
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
-
Male
-
Prognosis
-
Retrospective Studies
Substances
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors